July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Retinal vascular structure independently predicts initial treatment-response in neovascular age-related macular degeneration
Author Affiliations & Notes
  • Kathrine Leth-Møller
    Odense University Hospital, Odense C, Denmark
  • Ditte Borup Jakobsen
    Odense University Hospital, Odense C, Denmark
  • Anna Stage Vergmann
    Odense University Hospital, Odense C, Denmark
  • Thomas Lee Torp
    Odense University Hospital, Odense C, Denmark
  • Einar Stefansson
    Department of Ophthalmology, National Hospital Reykjavik, Reykjavik, Iceland
  • Tunde Peto
    School of Medicine, Dentistry and Biomedical Sciences, Queens University Belfast, Belfast, Ireland
  • Jakob Grauslund
    Odense University Hospital, Odense C, Denmark
  • Footnotes
    Commercial Relationships   Kathrine Leth-Møller, None; Ditte Jakobsen, None; Anna Stage Vergmann, None; Thomas Lee Torp, None; Einar Stefansson, None; Tunde Peto, None; Jakob Grauslund, Bayer (S), Novartis (S)
  • Footnotes
    Support  VELUX FONDEN
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3255. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kathrine Leth-Møller, Ditte Borup Jakobsen, Anna Stage Vergmann, Thomas Lee Torp, Einar Stefansson, Tunde Peto, Jakob Grauslund; Retinal vascular structure independently predicts initial treatment-response in neovascular age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3255.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : We aimed to determine if specific markers of retinal vascular structure are able to predict the initial treatment-response in treatment-naïve patients with neovascular age-related macular degeneration (nAMD).

Methods : Fifty eight eyes of 58 patients with treatment-naïve nAMD were included at baseline (BL). At BL, advanced markers of retinal vascular structure were measured by a trained grader using a semi-automated software (Singapore I Vessel Assessment, version 4.0, Singapore). Patients were treated with three monthly intravitreal injections with 2.0 mg aflibercept. One month after the last injection, patients were categorized as full treatment responders (FTR) or none/partial responders according to predefined criterias. Four eyes were excluded due to missing data at follow-up (F/U). A full treatment response was defined as loss of < 5 Early Treatment Diabetic Retinopathy Study Letters and no residual intra- or subretinal fluid and no macular hemorrhage.

Results : Median age was 79 years, 30.0% were male, 28.3% were active smokers, and 9.4% had diabetes. Of the 54 eyes attending F/U, 24 (44.4%) were full treatment responders, and 30 (55.6%) were none/partial responders. Median age in FTR patients was higher at baseline (81.5 vs. 77 years, p=0.04), but otherwise there was no statistically significant difference in gender, smoking or diabetes between groups (p>0,5for all). In addition, FTR had a lower venular length-diameter ratio (LDR) (7.3 vs. 15.9, p=0.0063), but did not differ according to arteriolar LDR, central retinal arteriolar or venular equivalent, branching angles, branching coefficients, junctional exponent deviation, or tortuosity. In an age- and sex-adjusted multiple logistic regression model, increasing venular LDR was independently associated with a lower chance of FTR (odds ratio 0.89 per 1-point increment in venular LDR, 95% confidence interval 0.82-0.98, p=0.021).

Conclusions : Higher retinal venular LDR is independently associated with an 11 % lower chance of FTR in patients with nAMD. If confirmed by larger, longitudinal studies, this could be used to personalize treatment by stratifying patients according to their potential future treatment demands.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.